1. Home
  2. WH vs GKOS Comparison

WH vs GKOS Comparison

Compare WH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WH
  • GKOS
  • Stock Information
  • Founded
  • WH 2017
  • GKOS 1998
  • Country
  • WH United States
  • GKOS United States
  • Employees
  • WH N/A
  • GKOS N/A
  • Industry
  • WH Hotels/Resorts
  • GKOS Medical/Dental Instruments
  • Sector
  • WH Consumer Discretionary
  • GKOS Health Care
  • Exchange
  • WH Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • WH 6.5B
  • GKOS 5.8B
  • IPO Year
  • WH N/A
  • GKOS 2015
  • Fundamental
  • Price
  • WH $87.76
  • GKOS $98.31
  • Analyst Decision
  • WH Strong Buy
  • GKOS Strong Buy
  • Analyst Count
  • WH 11
  • GKOS 13
  • Target Price
  • WH $106.70
  • GKOS $135.15
  • AVG Volume (30 Days)
  • WH 1.3M
  • GKOS 832.7K
  • Earning Date
  • WH 07-23-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • WH 1.86%
  • GKOS N/A
  • EPS Growth
  • WH 48.31
  • GKOS N/A
  • EPS
  • WH 4.22
  • GKOS N/A
  • Revenue
  • WH $1,416,000,000.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • WH $7.69
  • GKOS $27.88
  • Revenue Next Year
  • WH $6.55
  • GKOS $27.60
  • P/E Ratio
  • WH $20.86
  • GKOS N/A
  • Revenue Growth
  • WH 2.61
  • GKOS 23.92
  • 52 Week Low
  • WH $70.08
  • GKOS $77.10
  • 52 Week High
  • WH $113.07
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • WH 59.89
  • GKOS 45.42
  • Support Level
  • WH $83.45
  • GKOS $103.08
  • Resistance Level
  • WH $91.08
  • GKOS $106.82
  • Average True Range (ATR)
  • WH 1.96
  • GKOS 3.28
  • MACD
  • WH 0.96
  • GKOS -0.34
  • Stochastic Oscillator
  • WH 72.67
  • GKOS 2.80

About WH Wyndham Hotels & Resorts Inc.

As of Dec. 31, 2024, Wyndham Hotels & Resorts operates 903,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: